Cilostazol, Isosorbide Mononitrate Combination Well-Tolerated in Lacunar Stroke
April 26th 2019An escalating, combination dose of isosorbide mononitrate and cilostazol was shown to be well tolerated, with 72% of patients achieving full or ≥50% partial doses, the primary outcome, by the end of the 8-week treatment period.
FDA Issues Stroke Risk Reminder for Improper Use of Wingspan Stent System
April 26th 2019The FDA issued a reminder that improper use of the Stryker Wingspan Stent System can result in an increased risk for stroke or mortality. The agency advises against using the system when the onset of symptoms is within 7 days or less of treatment or for the treatment of transient ischemic attacks.
NuPlasma Young Blood Plasma Shows Positive 3-Month Data in Parkinson Disease
April 25th 2019NuPlasma yFFP was associated with improvements in complications of therapy, motor examination scores, mentation, behavior, and mood, and in activities of daily living in patients with Parkinson disease.
Nusinersen Improves Function in Patients With Later-Onset SMA
April 25th 2019Over the course of approximately 3 years, Hammersmith Functional Motor Scale-Expanded and Upper Limb Module scores, as well as 6-Minute Walk Test distances, improved significantly in patients with SMA type 2 and type 3.
pNF-H Has Potential As Biomarker of Spinal Muscular Atrophy Disease Activity
April 24th 2019Infants with SMA—who have elevated pNF-H levels—experienced significant drops in pNF-H levels when treated with nusinersen (Spinraza, Biogen), suggestive of pNF-H’s potential as a biomarker of disease activity and treatment response.
Teva Halts Clinical Development of Fremanezumab for Cluster Headache
April 23rd 2019A prespecified futility analysis of a phase 3 study revealed that the primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met.
Eptinezumab Endeavors to Maintain Migraine Prevention Progress
April 23rd 2019The chief executive officer of Alder Biopharmaceuticals detailed where the intravenous anti-CGRP treatment will fit into the marketplace and how the migraine prevention therapy will make an impact in treating patients.
New Acute Migraine Co-Primary End Points Provide Positives for Trial Design
April 22nd 2019A review of newly implemented primary end points—pain freedom and most bothersome symptom freedom at 2 hours—used in 8 clinical trials may help to guide future migraine researchers in the design of acute treatment trials.
Integrative Health and Parkinson Disease
April 18th 2019It has been estimated that between 40% and 60% of patients with PD use at least one form of complementary medicine. In this podcast, neurologist Sarah Mulukutla, MD, MPH talks about CAM options for neurologists to discuss with their patients.